Performance of clinical risk scores and prediction models to identify pathogenic germline variants in patients with advanced prostate cancer.

Autor: Rebhan K; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.; Departments of Urology and Pediatric Urology, Klinik Ottakring, Vienna, Austria., Stelzer PD; Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria., Pradere B; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.; Department of Urology, La Croix Du Sud Hospital, Quint Fonsegrives, France., Rajwa P; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.; Department of Urology, Medical University of Silesia, Zabrze, Poland., Kramer G; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria., Hofmann B; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria., Resch I; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria., Yurdakul O; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria., Laccone FA; Institute of Medical Genetics, Medical University of Vienna, Vienna, Austria., Bujalkova MG; Institute of Medical Genetics, Medical University of Vienna, Vienna, Austria., Smogavec M; Institute of Medical Genetics, Medical University of Vienna, Vienna, Austria., Tan YY; Department of Obstetrics, Gynecology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria., Ristl R; Center for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria., Shariat SF; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.; Departments of Urology, Weill Cornell Medical College, New York, NY, USA.; Department of Urology, University of Texas Southwestern, Dallas, TX, USA.; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic.; Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.; Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan.; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria., Egger G; Department of Pathology, Medical University of Vienna, Vienna, Austria.; Ludwig Boltzmann Institute Applied Diagnostics, Vienna, Austria.; Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria., Hassler MR; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. melanie.hassler-difratta@meduniwien.ac.at.

Publikováno v: World journal of urology [World J Urol] 2023 Aug; Vol. 41 (8), pp. 2091-2097. Date of Electronic Publication: 2023 Aug 01.

Partial loss of heterozygosity events at the mutated gene in tumors from MLH1/MSH2 large genomic rearrangement carriers.

Autor: Zavodna K; Laboratory of Cancer Genetics, Cancer Research Institute of Slovak Academy of Sciences, Vlarska 7, 833 91 Bratislava, Slovak Republic. katarina.zavodna@savba.sk, Krivulcik T, Bujalkova MG, Slamka T, Martinicky D, Ilencikova D, Bartosova Z

Publikováno v: BMC cancer [BMC Cancer] 2009 Nov 20; Vol. 9, pp. 405. Date of Electronic Publication: 2009 Nov 20.